Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin heavy chain 8 (MYH8) encodes a class II myosin motor protein primarily expressed in fetal human skeletal muscle, where it forms part of the hexameric myosin complex essential for muscle contraction[1][6]. MYH8 possesses ATPase enzymatic activity, enabling it to hydrolyze ATP and convert chemical energy into mechanical force through interaction with actin filaments[1][3][7]. Mutations in this gene are causally linked to Trismus-pseudocamptodactyly syndrome, a rare congenital arthrogryposis affecting the jaw and fingers[1][2]. MYH8 is mainly involved in normal muscle development and contraction and is not a common direct therapeutic target or receptor for small molecules or biologics[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin heavy chain 8 (MYH8).